Trials / Completed
CompletedNCT00192842
Gemcitabine With Curcumin for Pancreatic Cancer
Phase II Trial of Gemcitabine and Curcumin in Patients With Advanced Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Rambam Health Care Campus · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study hypotheasis is that curcumin, a natural compound with a potent antiproliferative effect, can improve the efficacy of the standard chemotherapy gemcitabine in patients with advanced pancreatic cancer. That is why the patients are given a daily oral dose of 8 gr of curcumin along the chemotherapeutic protocol of weekly gemcitabine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | curcumin (+ gemcitabine) |
Timeline
- Start date
- 2004-07-01
- Primary completion
- 2007-11-01
- Completion
- 2010-09-01
- First posted
- 2005-09-19
- Last updated
- 2010-09-22
Source: ClinicalTrials.gov record NCT00192842. Inclusion in this directory is not an endorsement.